OBJECTIVE: To examine whether prior statin use affects outcome and intracranial hemorrhage (ICH) rates in stroke patients receiving IV thrombolysis (IVT). METHODS: In a pooled observational study of 11 IVT databases, we compared outcomes between statin users and nonusers. Outcome measures were excellent 3-month outcome (modified Rankin scale 0-1) and ICH in 3 categories. We distinguished all ICHs (ICH(all)), symptomatic ICH based on the criteria of the ECASS-II trial (SICH(ECASS-II)), and symptomatic ICH based on the criteria of the National Institute of Neurological Disorders and Stroke (NINDS) trial (SICH(NINDS)). Unadjusted and adjusted odds ratios (OR) with 95% confidence intervals were calculated. RESULTS: Among 4,012 IVT-treated patients, 918 (22.9%) were statin users. They were older, more often male, and more frequently had hypertension, hypercholesterolemia, diabetes, coronary heart disease, and concomitant antithrombotic use compared with nonusers. Fewer statin users (35.5%) than nonusers (39.7%) reached an excellent 3-month outcome (OR(unadjusted) 0.84 [0.72-0.98], p = 0.02). After adjustment for age, gender, blood pressure, time to thrombolysis, and stroke severity, the association was no longer significant (0.89 [0.74-1.06], p = 0.20). ICH occurred by trend more often in statin users (ICH(all) 20.1% vs 17.4%; SICH(NINDS) 9.2% vs 7.5%; SICH(ECASS-II) 6.9% vs 5.1%). This difference was statistically significant only for SICH(ECASS-II) (OR = 1.38 [1.02-1.87]). After adjustment for age, gender, blood pressure, use of antithrombotics, and stroke severity, the OR(adjusted) for each category of ICH (ICH(all) 1.15 [0.93-1.41]; SICH(ECASS-II) 1.32 [0.94-1.85]; SICH(NINDS) 1.16 [0.87-1.56]) showed no difference between statin users and nonusers. CONCLUSION: In stroke patients receiving IVT, prior statin use was neither an independent predictor of functional outcome nor ICH. It may be considered as an indicator of baseline characteristics that are associated with a less favorable course.
OBJECTIVE: To examine whether prior statin use affects outcome and intracranial hemorrhage (ICH) rates in strokepatients receiving IV thrombolysis (IVT). METHODS: In a pooled observational study of 11 IVT databases, we compared outcomes between statin users and nonusers. Outcome measures were excellent 3-month outcome (modified Rankin scale 0-1) and ICH in 3 categories. We distinguished all ICHs (ICH(all)), symptomatic ICH based on the criteria of the ECASS-II trial (SICH(ECASS-II)), and symptomatic ICH based on the criteria of the National Institute of Neurological Disorders and Stroke (NINDS) trial (SICH(NINDS)). Unadjusted and adjusted odds ratios (OR) with 95% confidence intervals were calculated. RESULTS: Among 4,012 IVT-treated patients, 918 (22.9%) were statin users. They were older, more often male, and more frequently had hypertension, hypercholesterolemia, diabetes, coronary heart disease, and concomitant antithrombotic use compared with nonusers. Fewer statin users (35.5%) than nonusers (39.7%) reached an excellent 3-month outcome (OR(unadjusted) 0.84 [0.72-0.98], p = 0.02). After adjustment for age, gender, blood pressure, time to thrombolysis, and stroke severity, the association was no longer significant (0.89 [0.74-1.06], p = 0.20). ICH occurred by trend more often in statin users (ICH(all) 20.1% vs 17.4%; SICH(NINDS) 9.2% vs 7.5%; SICH(ECASS-II) 6.9% vs 5.1%). This difference was statistically significant only for SICH(ECASS-II) (OR = 1.38 [1.02-1.87]). After adjustment for age, gender, blood pressure, use of antithrombotics, and stroke severity, the OR(adjusted) for each category of ICH (ICH(all) 1.15 [0.93-1.41]; SICH(ECASS-II) 1.32 [0.94-1.85]; SICH(NINDS) 1.16 [0.87-1.56]) showed no difference between statin users and nonusers. CONCLUSION: In strokepatients receiving IVT, prior statin use was neither an independent predictor of functional outcome nor ICH. It may be considered as an indicator of baseline characteristics that are associated with a less favorable course.
Authors: Jan F Scheitz; Rachael L MacIsaac; Azmil H Abdul-Rahim; Bob Siegerink; Philip M Bath; Matthias Endres; Kennedy R Lees; Christian H Nolte Journal: Neurology Date: 2016-03-25 Impact factor: 9.910
Authors: Manuel Cappellari; Paolo Bovi; Giuseppe Moretto; Andrea Zini; Patrizia Nencini; Maria Sessa; Mauro Furlan; Alessandro Pezzini; Giovanni Orlandi; Maurizio Paciaroni; Tiziana Tassinari; Gaetano Procaccianti; Vincenzo Di Lazzaro; Luigi Bettoni; Carlo Gandolfo; Giorgio Silvestrelli; Maurizia Rasura; Giuseppe Martini; Maurizio Melis; Maria Vittoria Calloni; Fabio Chiodo-Grandi; Simone Beretta; Maria Guarino; Maria Concetta Altavista; Simona Marcheselli; Giampiero Galletti; Laura Adobbati; Massimo Del Sette; Armando Mancini; Daniele Orrico; Serena Monaco; Anna Cavallini; Rossella Sciolla; Francesco Federico; Umberto Scoditti; Fabio Brusaferri; Claudio Grassa; Luigi Specchio; Maria Roberta Bongioanni; Marco Sparaco; Mauro Zampolini; Gabriele Greco; Rinaldo Colombo; Bruno Passarella; Alessandro Adami; Domenico Consoli; Danilo Toni Journal: Neurology Date: 2013-01-23 Impact factor: 9.910
Authors: William J Meurer; Heemun Kwok; Lesli E Skolarus; Eric E Adelman; Allison M Kade; Jack Kalbfleisch; Shirley M Frederiksen; Phillip A Scott Journal: Acad Emerg Med Date: 2013-02 Impact factor: 3.451
Authors: Valerian L Altersberger; Lars Kellert; Abdulaziz S Al Sultan; Nicolas Martinez-Majander; Christian Hametner; Ashraf Eskandari; Mirjam R Heldner; Sophie A van den Berg; Andrea Zini; Visnja Padjen; Georg Kägi; Alessandro Pezzini; Alexandros Polymeris; Gian M DeMarchis; Marjaana Tiainen; Silja Räty; Stefania Nannoni; Simon Jung; Thomas P Zonneveld; Stefania Maffei; Leo Bonati; Philippe Lyrer; Gerli Sibolt; Peter A Ringleb; Marcel Arnold; Patrik Michel; Sami Curtze; Paul J Nederkoorn; Stefan T Engelter; Henrik Gensicke Journal: Eur Stroke J Date: 2019-11-13